Are you Dr. Srour?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-798-2619
Summary
- Dr. Samer Srour, MD is a hematologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2006 - 2009
Beirut Arab University Faculty of MedicineClass of 2003
Certifications & Licensure
FL State Medical License 2021 - Present
OK State Medical License 2008 - 2025
TX State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- 27 citationsPost-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.Rohtesh S Mehta, Rima M Saliba, Gabriela Rondon, Gheath Al-Atrash, Qaiser Bashir
Transplantation and Cellular Therapy. 2022-10-01 - 5 citationsImpact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.Oren Pasvolsky, Denái R Milton, Mikael Rauf, Sassine Ghanem, Adeel Masood
Blood Cancer Journal. 2023-05-03 - 7 citationsOutcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.Oren Pasvolsky, Sassine Ghanem, Denái R Milton, Adeel Masood, Mark R Tanner
Transplantation and Cellular Therapy. 2023-12-01
Press Mentions
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023- Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual MeetingMarch 15th, 2023
- Updated Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell TherapyDecember 20th, 2022
- Join now to see all
